KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Construction in Progress (2016)

Historic Construction in Progress for Jazz Pharmaceuticals (JAZZ) over the last 7 years, with Q1 2016 value amounting to $66.2 million.

  • Jazz Pharmaceuticals' Construction in Progress rose 3385.04% to $66.2 million in Q1 2016 from the same period last year, while for Mar 2016 it was $66.2 million, marking a year-over-year increase of 3385.04%. This contributed to the annual value of $63.0 million for FY2015, which is 6962.71% up from last year.
  • Jazz Pharmaceuticals' Construction in Progress amounted to $66.2 million in Q1 2016, which was up 3385.04% from $63.0 million recorded in Q4 2015.
  • In the past 5 years, Jazz Pharmaceuticals' Construction in Progress ranged from a high of $66.2 million in Q1 2016 and a low of $148000.0 during Q1 2012
  • In the last 5 years, Jazz Pharmaceuticals' Construction in Progress had a median value of $10.6 million in 2014 and averaged $24.0 million.
  • Its Construction in Progress has fluctuated over the past 5 years, first soared by 123918.92% in 2013, then surged by 3385.04% in 2016.
  • Jazz Pharmaceuticals' Construction in Progress (Quarter) stood at $1.1 million in 2012, then surged by 286.61% to $4.4 million in 2013, then soared by 746.51% to $37.1 million in 2014, then soared by 69.63% to $63.0 million in 2015, then rose by 5.04% to $66.2 million in 2016.
  • Its last three reported values are $66.2 million in Q1 2016, $63.0 million for Q4 2015, and $61.1 million during Q3 2015.